Answers are grounded in this paper and cite their sources.
INTRODUCTION: Eptinezumab is the only anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered intravenously for migraine prevention. Randomized trials have shown efficacy in episodic and chronic migraine, including after previous preventive failures, but strict eligibility criteria limit their generalizability to routine care. AREAS COVERED: This review summarizes the pharmacology and pivotal trials of eptinezumab and examines real-world studies of its effectiveness and safety, identified through a PubMed search up to October 2026. Particular attention is given to patients with previous anti-CGRP antibody failure, medication overuse and cardiovascular disease, and to the limitations of the available evidence. EXPERT OPINION: Real-world cohorts confirm a rapid onset and a clinically relevant benefit in broader and more refractory populations, with mostly mild and transient adverse events, although hypersensitivity reactions during infusion deserve attention. Effect sizes vary widely and are likely inflated by analyses restricted to patients who remain on treatment. Previous response to an antibody may predict benefit better than previous failure. Priorities are controlled switching studies, predictors of response and prospective evidence on when to judge treatment and whom to escalate to 300 mg.
No takes yet. Share an insight, caveat, or question.
Pellesi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: